FEBS Open Bio
John Wiley and Sons Inc.
Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis
Volume: 10 , Issue: 6
Doi: 10.1002/2211-5463.12866

Table of Contents




Autoimmune pancreatitis frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. Due to their significant immunomodulatory capabilities, mesenchymal stromal cells (MSCs) have been proposed as a novel treatment strategy for various immune and inflammatory pathologies including those with autoimmune origins. Here, we not only highlight the most recent MSC live‐cell experiments to address acute pancreatitis, but also discuss the opportunities afforded by the emergence of the newly identified field of MSC necrobiology.

Goodman and Davies: Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis



acute graft‐versus‐host disease






mesenchymal stromal cell




tumor necrosis factor‐α


tumor necrosis factor‐α‐induced gene/protein 6


vascular endothelial growth factor

Autoimmune pancreatitis is a form of chronic pancreatitis that frequently causes acute episodes with clinical symptoms parallel to those of acute pancreatitis. If these acute inflammatory episodes are not properly managed, they can cause pancreatic fibrosis which can lead to the development of pancreatic cancer as well as the loss of exocrine and endocrine functions [1]. The disease is currently most commonly dealt with through the use of corticosteroids [2]. In around 90% of cases, corticosteroids are effective in the treatment of autoimmune pancreatitis [2]. However, for the other 10% of patients whose conditions do not respond favorably to corticosteroids, there is a lack of options. Of importance to note is that corticosteroids have, in some cases, been shown to provoke side effects including osteoporosis, hypertension, diabetes, weight gain, increased vulnerability to infection, cataracts, and glaucoma, thinning of the skin, and muscle weakness [3]. In terms of alternatives, the immunomodulator, thiopurine, and an anti‐CD20 monoclonal antibody, rituximab, are occasionally used to treat autoimmune pancreatitis; however, their success rates are variable [2]. For these reasons, there is considerable demand for a novel and superior strategy to manage the symptoms of autoimmune pancreatitis.

We recently (2019) summarized the available scientific literature pertaining to the putative use of mesenchymal stromal cells (MSCs) as a treatment strategy for acute pancreatitis [4]. In brief, we highlighted how MSCs, through various studies, have been proven to abrogate the effects of acute pancreatitis in rodent models. We also discussed the lack of clarity in current experimental designs that fail to take the original cause of acute pancreatitis into account. This is problematic because MSCs clearly would not be an ideal therapeutic strategy for gallstones or alcohol‐induced pancreatitis which already possesses successful treatment regimens. Here, we provide updates on new approaches reported in the field, and also discuss the use of MSC derivatives in the treatment of autoimmune pancreatitis.

Mesenchymal stromal cells were once thought to mitigate various pathologies solely through anti‐inflammatory and tissue regenerative pathways. Autologous MSC therapy gained its first regulatory approval, for the treatment of acute myocardial infarction, in 2011 [5] although not without creating some continuing controversy [6]. In fact, MSCs have been shown to exhibit an immunomodulatory phenotype through four distinct mechanisms [7] (Fig. 1). The latter include modulating the proliferation and differentiation of dendritic, B, and T cells and mediating the polarization of monocytes from an inflammatory M1 phenotype to an anti‐inflammatory M2 phenotype. In addition, MSCs can reduce the production of reactive oxygen species such as superoxide anions, which inhibit the apoptosis of neutrophils. Finally, MSCs can diminish endothelial cell responses to pro‐inflammatory cytokines such as TNF‐α, IL‐1, and IFN‐γ [7].

The immunomodulatory effects of MSCs all have demonstrated proven efficacy in models of chronic inflammatory and autoimmune diseases. Included with permission from Munir and McGettrick [7].
Fig. 1
The immunomodulatory effects of MSCs all have demonstrated proven efficacy in models of chronic inflammatory and autoimmune diseases. Included with permission from Munir and McGettrick [7].

MSCs for the treatment of immune pathologies

Due to their significant immunomodulatory capabilities, MSCs have been proposed as a novel treatment strategy for various pathologies wherein the immune system is either compromised or dysfunctional, including those with autoimmune origins (Fig. 2). Indeed, MSCs have shown success in the treatment of systemic lupus erythematosus [8], rheumatoid arthritis [9], type 1 diabetes mellitus [10], multiple sclerosis [11], liver failure associated with hepatitis B virus [12], ulcerative colitis [13], dacryoadenitis [14], Sjögren's syndrome [15], and systemic scleroderma [15]. A very recent example is the co‐administration of MSCs with pancreatic islets in immunocompetent type 1 diabetic wild‐type mice. Glycemic control was restored, using human mesenchymal cells, and a clear demonstration provided evidence of the suppression of T‐cell activation without the need for prior ex vivo licensing (stimulation) with the inflammatory cytokines interferon‐Υ (IFN‐Υ), interleukin‐1β (IL‐1β), and tumor necrosis factor‐α (TNF‐α) [16]. The first approval, with government reimbursement, for the treatment of an immune condition with MSCs was that in Japan in 2016, for the treatment of both pediatric disease and adult acute graft‐versus‐host disease (aGVHD) [17]. Thus, the acute inflammatory episodes of autoimmune pancreatitis may represent an appropriate therapeutic target for MSCs in cases refractory to the use of corticosteroids.

Pictorial representation of the distinct categories of pathologies for which MSC therapy is being investigated through clinical trials. Data from 954 trials were obtained by searching registered clinical trials on https://clinicaltrials.gov/, using keywords ‘mesenchymal stem cell, mesenchymal stromal cells, MSC, mesenchymal progenitor cells, multi stem cells, Pluristem PLXPAD, PDA002/001, adipose derived mesenchymal stem cell, adipose derived mesenchymal stromal cell, adipose derived MSC, ADMSC, adipose derived regenerative cell, CX610 and CX611’. Of importance to note is that this data set includes clinical trials that are recruiting, completed, or abandoned.
Fig. 2
Pictorial representation of the distinct categories of pathologies for which MSC therapy is being investigated through clinical trials. Data from 954 trials were obtained by searching registered clinical trials on https://clinicaltrials.gov/, using keywords ‘mesenchymal stem cell, mesenchymal stromal cells, MSC, mesenchymal progenitor cells, multi stem cells, Pluristem PLXPAD, PDA002/001, adipose derived mesenchymal stem cell, adipose derived mesenchymal stromal cell, adipose derived MSC, ADMSC, adipose derived regenerative cell, CX610 and CX611’. Of importance to note is that this data set includes clinical trials that are recruiting, completed, or abandoned.

Recent cellular approaches

One recent approach has pretreated (licensed) umbilical‐derived mesenchymal stromal cells with angiotensin II before employing them in the treatment of severe acute pancreatitis in Sprague‐Dawley rats [18]. The rationale was to maximize the constitutive angiogenic properties of UCMSCs. The pretreated cells demonstrated an enhanced ability to abrogate pancreatitis compared with cells that had not been licensed. This conclusion was established through the histological assessment of pancreatic sections using measures of necrosis, edema, vacuolization, and inflammation as well as through the observation of myeloperoxidase and serum amylase levels. The treated cells were also shown to increase the paracrine release of vascular endothelial growth factor (VEGF) which has been proven to be an important factor in pancreatic tissue healing [18].

In another study, human adipose tissue‐derived mesenchymal stromal cells were transfected with siRNA targeting tumor necrosis factor‐α‐induced gene/protein 6 (TSG‐6) and compared with their untransduced, control counterparts in the treatment of caerulein and lipopolysaccharide‐induced severe acute pancreatitis in C57BL/6 mice. Pancreas‐to‐body weight ratio, tissue edema, necrosis of acinar cells, and inflammatory cell infiltration were all improved in the control group, demonstrating the role played by TSG‐6 in ameliorating the disease. Specifically, the pro‐inflammatory cytokines, TNF‐α, IL 1β, and IL‐6 levels, and markers of endoplasmic reticulum stress, Grp78, CHOP, and caspase‐12, were decreased, while anti‐inflammatory cytokine, IL‐10, was increased in the control group [19].

Ongoing challenges

While the above studies demonstrate convincing evidence that mesenchymal stromal cells could, in the future, be used as a novel treatment strategy for the acute episodes of autoimmune pancreatitis, it is important to acknowledge some limitations in the current scientific literature. Firstly, as we have previously discussed, to be clinically relevant, an animal model needs to be designed to specifically reflect the cause of the pancreatitis, such as autoimmune pancreatitis. Also, studies need to be conducted on the use of MSCs in large animal models whose gastroenterological anatomies are more similar to that of humans. Finally, as the cells are being proposed as a novel clinical therapy it is important to recognize barriers that could prove to be problematic as discussed below.

Mesenchymal stromal cells can be isolated from a plethora of human sources including adipose, brain, endometrial, placental, and umbilical cord tissue as well as bone marrow, cord blood, amniotic fluid, various regions of Wharton's jelly, and dental pulp [20, 21]. However, it is becoming increasingly clear that the functional phenotype of a particular population of MSCs varies with both the tissue source employed and the conditions under which the cells are culture‐expanded [22]. Despite these disparate origins, the overall abundance of MSCs in the human body is still relatively low, for example, only 0.001–0.01% of cells in the bone marrow are MSCs [20]. MSC therapy usually requires hundreds of millions of MSCs; in the aforementioned studies, 1 million cells were used in the study conducted on mice and 10 million cells were used on the rats [18, 19]. In an ongoing Phase III, human clinical trial being conducted for chronic graft‐versus‐host disease, a dose of 2 million cells per kilogram was injected six times intravenously [23]. Clearly, due to the scarce number of MSCs in the human body and the large number needed for putative therapy, a barrier might exist wherein the demand for cells needed for therapy cannot be met. In vitro cell expansion is the only way to yield such a high volume of cells, but this can take up to 10 weeks [24]. In addition, as described in the aforementioned studies, transfected or pretreated (licensed) cells have been proposed, which are more complicated and costly to produce.

Live cells, dead cells, and derivatives

Therapy with live MSCs has a singular advantage over the use of their derivatives: The cells can differentiate to provide the connective tissue stroma of the recipient organ [25]. However, although MSCs have been proposed to assist with the significant stromal tissue damage that occurs in pancreatitis, the cell implantation time is too short for differentiation to occur. The two most common methods of MSC delivery for acute pancreatitis are intravenous and intraperitoneal. Less than 1% of MSCs survive for over a week after intravenous administration [26, 27], while when injected intraperitoneally, after 20 min MSCs fail to be detected in peritoneal lavage fluid and begin to form large aggregates [28]. This evidence suggests that the main therapeutic benefit of mesenchymal stromal cells is in their immunomodulatory capacity. Thus, the therapeutic advantage of live MSCs over derivatives does not extend to the cells' immunoregulatory properties.

Recent literature describes the new and exciting field of ‘MSC necrobiology’, which proposes a novel solution to some of the aforementioned barriers. Necrobiology provides four mechanisms by which derivatives of mesenchymal stromal cells can maintain significant clinical efficacy: apoptosis, autophagy, mitochondrial transfer, and extracellular vesicles [29]. MSC products derived from these pathways have been proven to ameliorate a plethora of pathologies (Table 1). Indeed, MSC derivatives (Fig. 2) have, in some cases, been shown to be as therapeutically beneficial as living MSCs [30, 31, 32, 33], but have the advantage of being able to pass easily through the circulatory system.

Table 1
Details of published studies investigating the therapeutic efficacy of MSC derivatives originating from four distinct necrobiology pathways.
AuthorsMechanism/PathwayCondition(s) of interestResults
Galleu et al . [34]ApoptosisAllergic airway inflammation and Graft‐versus‐host disease

↓ Eosinophil infiltrate in bronchoalveolar lavage (BAL)


↓ Inflammatory endpoints

↑ Immunomodulation

Chang et al . [35]ApoptosisSepsis syndrome induced by cecal puncture and ligation

↓ Cecal and kidney injury

↓ TNF‐α

Chen et al . [36]ApoptosisKidney injury induced by sepsis↓ Kidney injury
Sung et al . [37]ApoptosisLung and kidney injury induced by sepsis syndrome

↓ Lung and kidney injury

↓ TNF‐α

↓ NF‐κB

Gao et al . [38]AutophagyThis study investigated generally if the activation of autophagy in MSCs ameliorates their immunosuppressive capacity

↑ TGF‐β1 secretion

↑ Immunomodulation

Yao et al . [39]Mitochondrial transferAsthma

↓ Asthma inflammation

↓ IL‐4, IL‐5, IL‐13

Li et al . [40]Mitochondrial transferAirway epithelial cell damage induced by cigarette smoke in chronic obstructive pulmonary disorder (COPD)↓ Lung injury
Zhang et al . [41]Mitochondrial transferCardiomyopathyImproved heart function
Morrison et al . [42]Mitochondrial transferAcute respiratory distress syndrome (ARDS)

↑ M2 macrophage expression

↓ TNF‐α

↓ IL‐8

Collino et al . [43]Extracellular vesicle derivationAcute kidney injury

↑ Renal tubular cell proliferation

↓ Renal tubular cell apoptosis

Lai et al . [44]Extracellular vesicle derivationMyocardial ischemia/reperfusion injury↑ Cardioprotective effects
Li et al . [45]Extracellular vesicle derivationAcute lung injury

↓ Oxidative stress injury

↓ Inflammatory response

Wu et al . [46]Extracellular vesicle derivationCutaneous injury

↑ Wnt4

↑14‐3‐3ζ protein

↑ Wound healing

Mesenchymal stromal cells that have undergone apoptosis have been shown to reduce inflammatory endpoints in mouse models of allergic airway inflammation induced by ovalbumin (OVA) causing noncytotoxic T helper‐type cell inflammation [34]. Apoptotic rat adipose‐derived MSCs have also been proven superior in ameliorating the condition of cecal ligation and puncture‐induced sepsis in rat models in comparison with living MSCs [35, 36, 37]. Autophagic mesenchymal stromal cells have also been proven to have therapeutic benefits. MSCs derived from human bone marrow that have undergone autophagy have been proven to regulate CD4+ T helper cells via TGF‐β1 signaling [38]. Similarly, when MSCs underwent autophagy as a result of the administration of rapamycin, their ability to suppress CD4+ T helper cell proliferation was improved [38]. MSCs subjected to mitochondrial transfer also seem to be effective in mitigating the symptoms of asthma [39], chronic obstructive pulmonary disorder [40], cardiomyopathy [41], acute respiratory distress syndrome, and sepsis [42]. There is also evidence that extracellular vesicles derived from MSCs hold clinical efficacy in pathologies of the kidney [43], heart [44], lung [45], and skin [46].

In recent years, exosome therapy for certain inflammatory conditions has garnered significant interest. Almost all cells in the human body can produce exosomes: Extracellular vesicles produced by an endosomal pathway are approximately 30–150 nm in size [47]. Exosomes were previously thought of as having the sole responsibility of clearing cellular debris; however, recent scientific literature points to their ability to modulate intracellular environmental conditions. It is believed that only certain exosomes are immunoregulatory. Thus, a subclass of exosomes has been described as ‘signalosomes’, which, when released from MSCs, have an exceptional capacity for immunoregulation [47].

Exosome therapy using ‘signalosomes’ has been investigated for a plethora of pathologies including diseases of the heart [48], lung [49], kidney [50], brain [51], liver [52], intestines [53], skin [54], and nervous system [55] as well as for sepsis [56] and various cancers [57, 58]. In 2014, a clinical trial was conducted using exosome therapy for steroid‐refractory graft‐vs‐host disease and showed positive results [59]. Another study that investigated the use of exosomes as a novel therapeutic strategy for neonatal chronic lung disease compared their efficacy to that of a whole MSC population [60]. The study indicated that exosomes themselves hold an equivalent and sometimes even superior ability to modulate the inflammatory response. The use of MSC derivatives for treatment holds several advantages over the use of a live MSC population. They can be less costly to produce and can last up to 6 months when stored at −20 °C [61]. Derivatives are also a safer treatment option compared with whole MSCs as there are no risks associated with mutagens or oncogenicity. However, it should be pointed out that there is no documented technique to isolate ‘signalosomes’ from exosomes derived from other biogenic pathways, which may not possess the same immunomodulatory capacity [47].

Exosomes, in general, can be isolated by several methods. One of the most common methods is ultracentrifugation, although this requires costly apparatus (for industrial scale‐up) and the technique can promote vesicle aggregation which is detrimental to the structural and metabolic integrity of the exosomes produced [62]. Milder techniques of isolation have been described, for example, gradient density isolation and size‐exclusion chromatography. However, these techniques also have issues as density‐based separation may lead to enrichment as opposed to true isolation which may result in the presence of unwanted particles [63, 64]. Additionally, this technique does not allow for the large‐scale bioprocessing of exosomes, therefore making it an unrealistic technique in the context of therapy [63, 64].

Fortunately, there are other MSC‐derived products that are disruptive since production technology is far simpler and less costly than producing exosomes. Studies have been conducted indicating that cellular lysates have a similar therapeutic benefit in the treatment of various pathologies as compared to exosomes and whole‐cell MSCs themselves. Eleven published studies use cellular lysate derived from mesenchymal stromal cells from different origins to treat diverse conditions. The studies investigate the lysate's effect on aging [65], erectile dysfunction [66], fulminant hepatic failure [67], stroke [68], osteosarcoma and mammary carcinoma [69], epilepsy [70], liver failure [71], wound healing [72], ischemia [73], lymphoma [74], and obesity [75]. All of the aforementioned studies except the study investigating its effects on aging demonstrated that the lysate was able to ameliorate in vitro and in vivo models.

Recently, MSC derivative therapy has been proven effective in treating pathologies that are autoimmune in nature. Apoptotic MSCs have demonstrated immunosuppressive properties in mouse models of GVHD [38], and extracellular vesicles have improved the symptoms associated with uveitis/uveoretinitis and type I diabetes mellitus [76]. In addition, exosomes have shown success in ameliorating autoimmune conditions including multiple sclerosis [77], Sjögren's syndrome [78], graft versus host disease [59], systemic lupus erythematosus [79], and rheumatoid arthritis [80]. These results suggest the potential use of derivatives for other autoimmune conditions that lack entirely favorable treatment regimens, such as autoimmune pancreatitis.


In conclusion, employing MSCs in the treatment of autoimmune pancreatitis remains a promising putative cell therapy. However, the recent emergence of a variety of methods to produce MSC derivatives provides a newer and simpler approach that could have significant advantages over the use of cells themselves including simpler production, lower regulatory barriers, and easier systemic transport upon intravenous delivery.

Conflict of interest

The authors declare no conflict of interest.



    GudaN and NøjgaardC (2015) . Recurrent acute pancreatitis and progression to chronic pancreatitis. Pancreapedia: The Exocrine Pancreas Knowledge Base47, , pp.653–666.


    OkazakiK, UchidaK, SumimotoK, MitsuyamaT, IkeuraT and TakaokaM (2014) . Autoimmune pancreatitis: pathogenesis, latest developments and clinical guidance. Ther Adv Chronic Dis5, , pp.104–111.


    BuchmanAL (2001) . Side effects of corticosteroid therapy. J Clin Gastroenterol33, , pp.289–294.


    GoodmanRR, JongMK and DaviesJE (2019) . Concise review: The challenges and opportunities of employing mesenchymal stromal cells in the treatment of acute pancreatitis. Biotechnol Adv, , pp.30005–30005.


    YangH (2011) . South Korea's stem cell approval. Nat Biotechnol29, , pp.857.


    SippD, RobeyPG and TurnerL (2018) . Clear up this stem‐cell mess. Nature561, , pp.455–457.


    MunirH and McGettrickHM (2015) . Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem Cells and Dev24, , pp.2091–2099.


    WangD, ZhangH, LiangJ, WangH, HuaB, FengX, GilkesonGS, FargeD, ShiS and SunL (2018) . A long‐term follow‐up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug‐resistant systemic lupus erythematosus. Stem Cell Reports10, , pp.933–941.


    WangL, HuangS, LiS, LiM, ShiJ, BaiW, WangQ, ZhengL and LiuY (2019) . Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. Drug Des Devel Ther13, , pp.4331–4340.


    WuH and MahatoRI (2014) . Mesenchymal stem cell‐based therapy for type 1 diabetes. Discov Med17, , pp.139–143.


    DulameaA (2015) . Mesenchymal stem cells in multiple sclerosis – translation to clinical trials. J Med Life8, , pp.24–27.


    ShiM, ZhangZ, XuR, LinH, FuJ, ZouZ, ZhangA, ShiJ, ChenL, LvSet al (2012) . Human mesenchymal stem cell transfusion is safe and improves liver function in acute‐on‐chronic liver failure patients. Stem Cells Transl Med1, , pp.725–731.


    HuJ, ZhaoG, ZhangL, QiaoC, DiA, GaoH and XuH (2016) . Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med12, , pp.2983–2989.


    LuX, WangX, NianH, YangD and WeiR (2017) . Mesenchymal stem cells for treating autoimmune dacryoadenitis. Stem Cell ResTher8, , pp.126.


    Sánchez‐BernáI, Santiago‐DíazC and Jiménez‐AlonsoJ (2015) . Immunomodulatory properties of stem mesenchymal cells in autoimmune diseases. Med Clin144, , pp.88–91.


    ForbesS, BondAR, ThirlwellKL, BurgoyneP, SamuelK, NobleJ, BorthwickG, ColliganD, McGowanNWA, LewisPSet al (2020) . Human umbilical cord perivascular cells improve human pancreatic islet transplant function by increasing vascularization. Sci Transl Med12, , pp.5907.




    YangJ, SuJ, XiS, KeX, ZhuY, LinH, ZengX, LiuB, ZhuM, DaiWYet al (2019) . Human umbilical cord mesenchymal stem cells pretreated with angiotensin‐II attenuate pancreas injury of rats with severe acute pancreatitis. Biomed Pharmaco117, 109052.


    LiQ, SongW, RyuM, NamA, AnJ, AhnJ, BhangDH, JungYC and YounH (2018) . TSG‐6 secreted by human adipose tissue‐derived mesenchymal stem cells ameliorates severe acute pancreatitis via ER stress downregulation in mice. Stem Cell Res Ther9, , pp.255–255.


    Marquez‐CurtisL, Janowska‐WieczorekA, McgannLE and ElliottJAW (2015) . Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects. Cryobiology71, , pp.181–197.


    DaviesJE, WalkerJT and KeatingA (2017) . Concise review: Wharton's jelly: the rich, but enigmatic, source of mesenchymal stromal cells. Stem Cells Transl Med6, , pp.1620–1630.


    BolandLK, BurandAJ, BoytDT, DobroskiH, DiL, LiszewskiJN, SchrodtMV, FrazerMK, SantillanDA and AnkrumJA (2019) . Nature vs. nurture: defining the effects of mesenchymal stromal cell isolation and culture conditions on resiliency to palmitate challenge. Front Immunol.10, 1080.




    VizosoF, EiroN, CidS, SchneiderJ and Perez‐FernandezR (2017) . Mesenchymal stem cell secretome: toward cell‐free therapeutic strategies in regenerative medicine. Int J Mol Sci18, 1852.


    HwangNS, ZhangC, HwangY and VargheseS (2009) . Mesenchymal stem cell differentiation and roles in regenerative medicine. Wiley Interdiscip Rev Syst Biol Med1, , pp.97–106.


    EggenhoferE, BenselerV, KroemerA, PoppFC, GeisslerEK, SchlittHJ, BaanCC, DahlkeMH and HoogduijnMJ (2012) . Mesenchymal stem cells are short‐lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol3, , pp.297–297.


    LeeRH, PulinAA, SeoMJ, KotaDJ, YlostaloJ, LarsonBL, Semprun‐PrietoL, DelafontaineP and ProckopDJ (2009) . Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti‐inflammatory protein TSG‐6. Cell Stem Cell5, , pp.54–63.


    BazhanovN, YlostaloJ, BartoshT, TiblowA, MohammadipoorA, FoskettA and ProckopD (2016) . Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs. Stem Cell Res Ther7, , pp.27.


    WeissDJ, EnglishK, KrasnodembskayaA, Isaza‐CorreaJ, HawthorneIJ and MahonBP (2019) . The necrobiology of mesenchymal stromal cells affects therapeutic efficacy. Front Immunol10, 1228.


    BakhtyarN, JeschkeM, HererE, SheikholeslamM and Amini‐NikS (2018) . Exosomes from acellular Wharton's jelly of the human umbilical cord promotes skin wound healing. Stem Cell Res Ther9, , pp.193.


    GonçalvesF, LukF, KorevaarS, BouzidR, PazA, López‐IglesiasC, BaanC, MerinoA and HoogduijnM (2017) . Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro‐inflammatory monocytes. Sci Rep7, , pp.12100.


    van KoppenA, JolesJA, van BalkomBas W M, LimSK, de KleijnD, GilesRH, VerhaarMC and DussauleJ (2012) . Human embryonic mesenchymal stem cell‐derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS ONE7, e38746.


    TimmersL, LimSK, ArslanF, ArmstrongJS, HoeferIE, DoevendansPA, PiekJJ, El OakleyRM, ChooA, LeeCNet al (2008) . Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res1, , pp.129–137.


    GalleuA, Riffo‐VasquezY, TrentoC, LomasC, DolcettiL, CheungTS, Von BoninM, BarbieriL, HalaiK, WardSet al (2017) . Apoptosis in mesenchymal stromal cells induces in vivo recipient‐mediated immunomodulation. Sci Transl Med9, , pp.7828–7839.


    ChangC, LeuS, SungH, ZhenY, ChoC, ChenA, TsaiT, ChungS, ChaiH, SunCKet al (2012) . Impact of apoptotic adipose‐derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J Transl Med10, , pp.244–244.


    ChenH, LinK, WallaceCG, ChenY, YangC, LeuS, ChenY, SunC, TsaiT, ChenYLet al (2014) . Additional benefit of combined therapy with melatonin and apoptotic adipose‐derived mesenchymal stem cell against sepsis‐induced kidney injury. J Pineal Res57, , pp.16–32.


    SungP, ChangC, TsaiT, ChangL, LeuS, ChenY, YangC, ChuaS, YehK, ChaiHTet al (2013) . Apoptotic adipose‐derived mesenchymal stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in rats. Stem Cell Res Ther4, , pp.155–155.


    GaoL, CenS, WangP, XieZ, LiuZ, DengW, SuH, WuX, WangS, LiJet al (2016) . Autophagy improves the immunosuppression of CD4+ T cells by mesenchymal stem cells through transforming growth factor‐β1. Stem Cells Transl Med5, , pp.1496–1505.


    YaoY, FanX, JiangD, ZhangY, LiX, XuZ, FangS, ChiuS, TseH, LianQet al (2018) . Connexin 43‐mediated mitochondrial transfer of iPSC‐MSCs alleviates asthma inflammation. Stem Cell Reports11, , pp.1120–1135.


    LiX, ZhangY, YeungSC, LiangY, LiangX, DingY, IpMSM, TseH, MakJCW and LianQ (2014) . Mitochondrial transfer of induced pluripotent stem cell‐derived mesenchymal stem cells to airway epithelial cells attenuates cigarette smoke‐induced damage. Am J Respir Cell Mol Biol51, , pp.455–465.


    ZhangY, YuZ, JiangD, LiangX, LiaoS, ZhangZ, YueW, LiX, ChiuS‐M, ChaiY‐Het al (2016) . iPSC‐MSCs with high intrinsic MIRO1 and sensitivity to TNF‐a yield efficacious mitochondrial transfer to rescue anthracycline‐induced cardiomyopathy. Stem Cell Reports7, , pp.749–763.


    MorrisonTJ, JacksonMV, CunninghamEK, KissenpfennigA, McauleyDF, O'KaneCM and KrasnodembskayaAD (2017) . Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med196, , pp.1275–1286.


    CollinoF, PomattoM, BrunoS, LindosoRS, TapparoM, SichengW, QuesenberryP and CamussiG (2017) . Exosome and microvesicle‐enriched fractions isolated from mesenchymal stem cells by gradient separation showed different molecular signatures and functions on renal tubular epithelial cells. Stem Cell Rev Rep13, , pp.226.


    LaiRC, ArslanF, LeeMM, SzeNSK, ChooA, ChenTS, Salto‐TellezM, TimmersL, LeeCN, El OakleyRMet al (2010) . Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res4, , pp.214–222.


    LiQC, LiangY and SuZB (2019) . Prophylactic treatment with MSC‐derived exosomes attenuates traumatic acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol316, , pp.L1107–L1117.


    WuP, ZhangB, ShiH, QianH and XuW (2018) . MSC‐exosome: a novel cell‐free therapy for cutaneous regeneration. Cytotherapy20, , pp.291–301.


    WillisGR, KourembanasS and MitsialisSA (2017) . Toward exosome‐based therapeutics: Isolation, heterogeneity, and fit‐for‐purpose potency. Front Cardiovasc Med4, , pp.63.


    YuB, KimHW, GongM, WangJ, MillardRW, WangY, AshrafM and XuM (2015) . Exosomes secreted from GATA‐4 overexpressing mesenchymal stem cells serve as a reservoir of anti‐apoptotic microRNAs for cardioprotection. Int J Cardiol182, , pp.349–360.


    LeeC, MitsialisSA, AslamM, VitaliSH, VergadiE, KonstantinouG, SdrimasK, Fernandez‐GonzalezA and KourembanasS (2012) . Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia‐induced pulmonary hypertension. Circulation126, , pp.2601–2611.


    ZhouY, XuH, XuW, WangB, WuH, TaoY, ZhangB, WangM, MaoF, YanYet al (2013) . Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin‐induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther4, , pp.34–34.


    KimD, NishidaH, AnSY, ShettyAK, BartoshTJ and ProckopDJ (2016) . Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc Natl Acad Sci USA113, , pp.170–175.


    TanCY, LaiRC, WongW, DanYY, LimSK and HoHK (2014) . Mesenchymal stem cell‐derived exosomes promote hepatic regeneration in drug‐induced liver injury models. Stem Cell Res Ther5, , pp.76.


    RagerTM, OlsonJK, ZhouY, WangY and BesnerGE (2016) . Exosomes secreted from bone marrow‐derived mesenchymal stem cells protect the intestines from experimental necrotizing enterocolitis. J Pediatr Surg51, , pp.942–947.


    FangS, XuC, ZhangY, XueC, YangC, BiH, QianX, WuM, JiK, ZhaoYet al (2016) . Umbilical cord‐derived mesenchymal stem cell‐derived exosomal microRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor‐β/SMAD2 pathway during wound healing. Stem Cells Transl Med5, , pp.1425–1439.


    BonafedeR, ScambiI, PeroniD, PotrichV, BoschiF, BenatiD, BonettiB and MariottiR (2016) . Exosome derived from murine adipose‐derived stromal cells: neuroprotective effect on in vitro model of amyotrophic lateral sclerosis. Exp Cell Res340, , pp.150–158.


    WangX, GuH, QinD, YangL, HuangW, EssandohK, WangY, CaldwellCC, PengT, ZingarelliBet al (2015) . Exosomal miR‐223 contributes to mesenchymal stem cell‐elicited cardioprotection in polymicrobial sepsis. Sci Rep5, , pp.13721–13721.


    OnoM, KosakaN, TominagaN, YoshiokaY, TakeshitaF, TakahashiR, YoshidaM, TsudaH, TamuraK and OchiyaT (2014) . Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal7, , pp.ra63.


    RoccaroAM, SaccoA, MaisoP, AzabAK, TaiY, ReaganM, AzabF, FloresLM, CampigottoF, WellerEet al (2013) . BM mesenchymal stromal cell‐derived exosomes facilitate multiple myeloma progression. J Clin Invest123, , pp.1542–1555.


    KordelasL, RebmannV, LudwigAK, RadtkeS, RuesingJ, DoeppnerTR, EppleM, HornPA, BeelenDW and GiebelB (2014) . MSC‐derived exosomes: a novel tool to treat therapy‐refractory graft‐versus‐host disease. Leukemia28, , pp.970.


    AslamM, BavejaR, LiangOD, Fernandez‐GonzalezA, LeeC, MitsialisSA and KourembanasS (2009) . Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med180, , pp.1122–1130.


    BatrakovaEV and KimMS (2016) . Development and regulation of exosome‐based therapy products. Wiley Interdiscip Rev Nanomed Nanobiotechnol8, , pp.744–757.


    LinaresR, TanS, GounouC, ArraudN and BrissonAR (2015) . High‐speed centrifugation induces aggregation of extracellular vesicles. J Extracell Vesicles4, 29509.


    WitwerKW, BuzásEI, BemisLT, BoraA, LässerC, LötvallJ, Nolte‐'T HoenEN, PiperMG, SivaramanS, SkogJet al (2013) . Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles2, , pp.20360.


    LiP, MaoZ, PengZ, ZhouL, ChenY, HuangP, TruicaCI, DrabickJJ, El‐DeiryW, DaoMet al (2015) . Acoustic separation of circulating tumor cells. Proc Natl Acad Sci USA112, , pp.4970–4975.


    HsuMF, YuSH, ChuangSJ, KuoTK, SingalPK, HuangCY, KaoCL and KuoCH (2018) . Can mesenchymal stem cell lysate reverse aging?Aging10, , pp.2900–2910.


    AlbersenM, FandelTM, LinG, WangG, BanieL, LinC and LueTF (2010) . Injections of adipose tissue‐derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med7, , pp.3331–3340.


    ParekkadanB, van PollD, SuganumaK, CarterEA, BerthiaumeF, TillesAW and YarmushML (2007) . Mesenchymal stem cell‐derived molecules reverse fulminant hepatic failure (MSC‐CM reverses FHF). PLoS ONE2, , pp.e941.


    JeonD, ChuK, LeeS, JungK, BanJ, ParkD, YoonH, JungS, YangH, KimBSet al (2013) . Neuroprotective effect of a cell‐free extract derived from human adipose stem cells in experimental stroke models. Neurobiol Dis54, , pp.414–420.


    GauthamanK, FongC, ArularasuS, SubramanianA, BiswasA, ChoolaniM and BongsoA (2013) . Human Wharton's jelly stem cell conditioned medium and cell‐free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice. J Cell Biochem114, , pp.366–377.


    ChuK, JeonD, LeeS, JungK, LeeS and RohJ (2010) . A cell‐free extract from human adipose stem cells protects mice against epilepsy. Annal Neurol68, , pp.S38.


    KhubutiyaM, TemnovA, VagabovV, SklifasA, RogovK and ZhgutovY (2015) . Effect of conditioned medium and bone marrow stem cell lysate on the course of acetaminophen‐induced liver failure. Bull Exp Biol Med159, , pp.118–123.


    MishraP, MishraP and BanerjeeD (2012) . Cell‐free derivatives from mesenchymal stem cells are effective in wound therapy. World J Stem Cells4, , pp.35–43.


    RajasinghJ, LambersE, HamadaH, BordE, ThorneT, GoukassianI, KrishnamurthyP, RosenKM, AhluwaliaD, ZhuYet al (2008) . Cell‐free embryonic stem cell extract‐mediated derivation of multi‐potent stem cells from NIH3T3 fibroblasts for functional and anatomical ischemic tissue repair. Cir Res102, , pp.e107–e117.


    LinH, FongC, BiswasA, ChoolaniM and BongsoA (2014) . Human Wharton's jelly stem cells, its conditioned medium and cell‐free lysate inhibit the growth of human lymphoma cells. Stem Cell Rev Rep10, , pp.573–586.


    LeeC, HsiaoW and LeeO (2017) . mesenchymal stem cell‐based therapies alleviate high‐fat diet‐induced obesity. Cytotherapy19, , pp.S224.


    Shigemoto‐KurodaT, OhJY, KimD, JeongHJ, ParkSY, LeeHJ, ParkJW, KimTW, AnSY, ProckopDJet al (2017) . MSC‐derived extracellular vesicles attenuate immune responses in two autoimmune murine models: type 1 diabetes and uveoretinitis. Stem Cell Reports8, , pp.1214–1225.


    RiazifarM, Rezza MohammadiM, PoneEJ, YeriA, LässerC, SegalinyAI, McIntyreLL, Vilas ShelkeG, HutchinsE, HamamotoAet al (2019) . Stem cell‐derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano13, , pp.6670–6688.


    HaiB, Shigemoto‐KurodaT, ZhaoQ, LeeRH and LiuF (2018) . Inhibitory effects of iPSC‐MSCs and their extracellular vesicles on the onset of sialadenitis in a mouse model of Sjögren's syndrome. Stem Cells Int2018, 2092315.


    SharmaJ, HamptonJM, ValienteGR, WadaT, SteigelmanH, YoungMC, SpurbeckRR, BlazekAD, BöshS, JarjourWNet al (2017) . Therapeutic development of mesenchymal stem cells or their extracellular vesicles to inhibit autoimmune‐mediated inflammatory processes in systemic lupus erythematosus. Front Immunol8, , pp.526.


    ChenZ, WangH, XiaY, YanF and LuY (2018) . Therapeutic potential of mesenchymal cell‐derived miRNA‐150‐5p‐expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF. J Immunol201, , pp.2472–2482.
https://test.researchpad.co/tools/openurl?pubtype=article&doi=10.1002/2211-5463.12866&title=Mesenchymal stromal cells and their derivatives – putative therapeutics in the management of autoimmune pancreatitis&author=Robbie R. Goodman,John E. Davies,&keyword=acute episodes,anti‐inflammatory,autoimmune pancreatitis,mesenchymal stromal cells,MSC derivatives,MSC necrobiology,&subject=Review Article,Review Article,